the psychedelic space is in its infancy - by any measure- the TGA reschedule brings it within reach as a significant treatment option - potential cure- for the indications being addressed - FDA reschedule is around the corner
Moving to establish clinics for delivery of psychedelic therapy in the only jurisdiction currently where that barrier to entry has been removed is an opportunity to relish - to have PW orchestrating that move is a stoke of unmatched good fortune from a business perspective alone
first mover will capture significant market share and world first tretment option outcomes .....
could it fail? of course it could
yet if successful the upside is substantial
https://www.nuwireinvestor.com/investing-in-psychedelic-stocks/
Incannex are not even on the radar yet - Clarion Clinics will certainly change that and bring Incannex into view ...Monash certainly is as a global research institute as listed above
https://www.monash.edu/medicine/scs/research/clinical-psychedelic-lab
the space will get more and more interesting across 2023 for Clarion Clinics ...no question - sit back and enjoy the ride as the global focus shifts to AU in this space..
